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*Nocardia* is an aerobic Gram-positive bacilli occurring ubiquitously in the environment, especially in soil, decomposing organic matter, vegetation, etc. The organism gains entry into the human body through inhalation or traumatic injury.\[[@ref1]\] Based on the route of entry, nocardiosis commonly manifests as pulmonary, cutaneous, or central nervous system disease. It gets disseminated from the primary source of inoculation to various parts of the body.\[[@ref2]\] Although commonly causing fatal disease in the immunocompromised, nocardiosis has also been reported in immunocompetent individuals.\[[@ref3]\] Pulmonary manifestations of nocardiosis may be subacute to chronic onset of productive or nonproductive cough, shortness of breath, chest pain, hemoptysis, and pleural effusion.\[[@ref1]\] Complications may include erosion of ribs and empyema necessitans.\[[@ref4]\]

Scrub typhus is a tropical infection caused by the obligate intracellular organism *Orientia tsutsugamushi*. Its prevalence is more pronounced in the tsutsugamushi triangle of South East Asian region. India thus falls under the tsutsugamushi triangle.\[[@ref5]\] Pulmonary manifestations in patients with scrub typhus include varying grades of bronchitis and interstitial pneumonitis progressing to acute respiratory distress syndrome.\[[@ref6]\]

Clinical manifestations of both these infections can be nonspecific due to overlapping clinical features. Lack of availability of rapid tests for diagnosing these infections makes early diagnosis difficult. Herein, we present a case of dual infection with pulmonary nocardiosis and scrub typhus in our critical care unit with fatal outcome.

C[ASE]{.smallcaps} R[EPORT]{.smallcaps} {#sec1-2}
=======================================

A 51-year-old male from a suburban town in Tamil Nadu, India, presented to our emergency department with a history of high-grade, intermittent fever and cough with expectoration for 15 days and breathlessness of 1-day duration. He was treated before hospitalization with nebulized bronchodilators, steroids, and quinolones. Significant past medical history included hypertension and childhood onset bronchial asthma requiring chronic steroid therapy. On admission to the ward, his symptoms persisted; examination findings revealed tachycardia, tachypnea, and bilateral crepitations with wheeze, more pronounced on the left side of the chest than the right \[[Table 1](#T1){ref-type="table"}\].

###### 

Clinical history and findings of the patient
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Due to respiratory distress, he was shifted to the multidisciplinary critical care unit. A thorough examination in critical care unit revealed an eschar on the left side of the chest typical of scrub typhus. Initially, the patient was placed on noninvasive ventilatory support. Dual coverage for scrub typhus with azithromycin and doxycycline was started. Since an outbreak of H1N1 cases was present, he was also empirically started on oseltamivir and throat swab for H1N1 by real-time polymerase chain reaction (RT PCR), and sepsis workup was initiated. He was intubated on the same day in view of worsening respiratory distress and hypoxemic respiratory failure. Antibiotics were escalated to meropenem and teicoplanin. Computed tomography (CT) scan of the brain, thorax, and abdomen was done after intubation. CT chest findings revealed bilateral multifocal patchy consolidation in both lungs, minimal right-sided pleural effusion, and collapse of left lung fields with consolidation \[[Figure 1](#F1){ref-type="fig"}\].

![Computed tomography chest and X-ray images of the patient showing consolidation of the left lung with destruction of the left lung](JGID-10-108-g002){#F1}

Tracheal aspirate sent for Gram stain showed moderate polymorphonuclear neutrophils with many branching filamentous bacilli suggestive of an actinomycete, probably *Nocardia* species \[[Figure 2](#F2){ref-type="fig"}\]. This was confirmed by a positive 1% acid-fast stain (modified Kinyoun method) \[[Figure 2](#F2){ref-type="fig"}\]. The patient was started immediately on cotrimoxazole and meropenem was changed to imipenem. Two further tracheal aspirates done consecutively also revealed similar Gram stain findings. All three tracheal cultures showed pure growth of dry chalky white colonies with pitting on blood agar and chocolate agar \[[Figure 3](#F3){ref-type="fig"}\]. Gram stain and 1% acid-fast stain from all cultures were consistent with preliminary findings. The organism was susceptible to amikacin, ciprofloxacin, linezolid, imipenem, and ceftriaxone, resistant to cotrimoxazole and amoxicillin -- clavulanate. Cotrimoxazole was stopped. Resistance to penicillin (10 U) was a supportive finding in identification of the organism \[[Figure 3](#F3){ref-type="fig"}\]. The final identification of *Nocardia* species was done by matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) as *Nocardia otitidiscaviarum* using standard protocols. MALDI-TOF MS works on the principle of mass spectrometry to identify microorganisms based on their mass to charge ratio. It has an excellent turnaround time for identifying multiple organisms within 3 h. In MALDI-TOF MS, the sample to be analyzed (bacterial colony) is mixed with another compound, called a matrix. Briefly, an isolated colony was picked up with a toothpick and spotted onto the MS slide. Once the colony dried, an on-plate extraction was performed using 1μl of 70% formic acid. Once this dried up, 1μl of HCCA matrix (α-Cyano-4-hydroxycinnamic acid) was added. The Vitek MS was set in the default IVD mode and spectra were analysed. Organism identification of 99.9% was considered correct to species level. The results are displayed as a series of lines (spectrum) which correspond to different fragments that have broken away from the original molecule.\[[@ref7]\] A database is then used to compare this pattern with the known data of yeasts and bacteria in the test system.
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Acid-fast stain for Mycobacteria was negative. HIV 1 and 2 antibodies were negative by chemiluminescence immunoassay. H1N1 RT-PCR was negative; oseltamivir was stopped. White blood cell counts were consistently high with a neutrophilic predominance. Progressive thrombocytopenia was noted (platelet count of 1.5 lakhs/mm^3^ on the day of admission dropped to 40,000/mm^3^). Scrub typhus IgM antibodies were positive by IgM ELISA (In Bios International, Inc., USA). The patient continued to require ventilatory support. Although transient improvement in hemodynamics was noted, there was subsequent deterioration with increasing inotropic requirement. Repeat blood cultures were sent on 5^th^ day after intubation which revealed yeast-like cells on Gram stain within 24 h in the automated blood culture system (BD BACTEC-9050). \[[Table 2](#T2){ref-type="table"}\] Caspofungin was given since the patient was hemodynamically unstable. *Candida tropicalis* was reported after 48 h being susceptible to Amphotericin B, fluconazole, voriconazole, caspofungin, and micafungin using Vitek 2 compact system (bioMérieux Clinical Diagnostics). On the 7^th^ day postadmission to the critical care unit, patient\'s condition remained critical with deranged renal parameters, liver function test, and coagulation profile. He was anuric with worsening metabolic acidosis and continued to deteriorate. Renal replacement therapy was initiated. The patient subsequently developed bradycardia followed by asystole and could not be resuscitated and was declared dead. The cause of death was sepsis with septic shock, multiorgan dysfunction, and community-acquired pneumonia -- nocardiosis, scrub typhus, and candidemia.

###### 

Significant microbiology laboratory findings
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Commonly, coinfections occur among patients with an underlying background of immunocompromised condition such as solid organ transplantation, stem cell transplant, long-term corticosteroid therapy, and acquired immunodeficiency syndrome due to HIV.\[[@ref6][@ref8]\] Pulmonary nocardiosis as such is seen commonly in patients with an underlying chronic lung disease, thereby increasing the list of its differential diagnosis such as Mycobacterial infections, fungal infections (pulmonary aspergillosis and pulmonary zygomycosis), lung malignancy, and actinomycosis.\[[@ref1]\] Coinfections have been commonly reported with tuberculosis and aspergillosis. A rare coinfection of nocardiosis with *Strongyloides stercoralis* has also been reported by authors from South India.\[[@ref9]\] Keeping this in mind, a thorough literature search did not reveal any reports of coinfection of pulmonary nocardiosis with scrub typhus thus far.

It is necessary to identify *Nocardia* up to their species level as there are variations in the susceptibility patterns of each species of *Nocardia*.\[[@ref10]\] Although cotrimoxazole is the first-line standard therapy of choice, the benefit of trimethoprim component is not clear.\[[@ref11]\] A retrospective evaluation submitted to the center for disease control and prevention on antimicrobial susceptibility of *Nocardia* isolates showed 42% resistance of *Nocardia* species to cotrimoxazole.\[[@ref12]\] The strain isolated from our patient was also resistant to cotrimoxazole. Our patient was treated with imipenem. According to two reviews on pulmonary nocardiosis, empirical combination therapy with amikacin and imipenem (or meropenem) or a three-drug regimen comprising of sulfonamides, amikacin, and either a carbapenem or third-generation cephalosporin can be used in such high-risk patients.\[[@ref2][@ref13]\]

On the other hand, scrub typhus coinfection has been observed with other tropical infections such as dengue, leptospirosis, malaria, melioidosis, mycoplasma, and Q fever. These coinfections with scrub typhus have been reported mostly from immunocompetent and young individuals.\[[@ref14][@ref15][@ref16][@ref17]\] Drugs advocated for the treatment of scrub typhus with pulmonary involvement are doxycycline and azithromycin.\[[@ref18]\] Our patient\'s empiric cover included both these antibiotics.

On reviewing three published case reports of nocardiosis with *Nocardia otitidiscaviarum*, one was from India and two from China, pulmonary involvement was seen in two cases, out of which one patient succumbed to the illness.\[[@ref3][@ref19][@ref20]\] However, coinfection with other microorganisms was not present in any of these cases, unlike our patient. Fatal outcomes in immunocompromised patients with coinfections are not infrequent. Mortality rates of nocardiosis in immunocompromised individuals has been reported to be 42.4% and due to scrub typhus to be 30%.\[[@ref21][@ref22]\] In spite of appropriate antibiotic therapy given to our patient on admission, one would wonder if earlier diagnosis on outpatient basis could have improved outcome although suspicion of coexistence of such infections may not be on top of the list for treating physicians.

C[ONCLUSION]{.smallcaps} {#sec1-4}
========================

We would like to emphasize that when any immunocompromised patient in India presents with nonspecific respiratory symptoms with atypical progression, it is necessary to keep in mind the possibility of more than one infection. A detailed history coupled with a thorough physical examination, early diagnosis, appropriate targeted therapy, and heightened awareness for coinfections are crucial for good clinical recovery in immunocompromised individuals. However, outcomes of coinfections such as nocardiosis and scrub typhus in an immunocompromised individual are worse than the general population.
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